Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Semaglutide Market Size to Reach USD 59.75 Billion by 2033, Experiencing High Demand for an Efficient Treatment for Diabetes and Obesity – SNS Insider

globenewswire.com
NVO The article highlights the strong market growth for semaglutide, with Ozempic and Wegovy (Novo Nordisk products) holding significant market share and expected to drive future growth. The demand for these treatments for diabetes and obesity is robust. HIMS Hims is identified as a telemedicine platform that has contributed to the increased adoption of prescription medications for weight management and diabetes, benefiting from the growing demand for semaglutide. CAL Calibrate is listed as a telemedicine platform that has boosted the uptake of prescription drugs for weight management and diabetes, aligning with the positive market trends for semaglutide.

Austin, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- According to SNS Insider, the Semaglutide Market size was valued at USD 27.79 billion in 2025 and is expected to reach USD 59.75 billion by 2033, growing at a CAGR of 10.04% during the forecast period of 2026-2033. The Semaglutide market is driven by the efficacy of semaglutide in treating type 2 diabetes and obesity, which provides substantial weight reduction and glycemic control compared to other available treatments. The penetration of insurance, favorable reimbursement policies, and expanding regulatory approvals in North America, Europe, and the developing world are also boosting the market beyond 2025.

Get a Sample Report of Semaglutide Market: https://www.snsinsider.com/sample-request/9268

The U.S. semaglutide market was valued at USD 17.11 billion in 2025E and is projected to reach USD 36.65 billion by 2033, at a CAGR of 9.99% from 2026 to 2033. The U.S. dominates the semaglutide market worldwide because of comprehensive insurance coverage, quick adoption by physicians, and high patient awareness. The growth of telemedicine platforms such as Ro, Hims, and Calibrate has also fueled the adoption of prescription medications for weight management and diabetes.

Semaglutide Market Size and Forecast

Superior Clinical Efficacy Driving Market Growth:

Superior clinical efficacy continues to be the primary driving force for the growth of the semaglutide market. Semaglutide was first approved for the treatment of type 2 diabetes. However, it has also received approvals for its use in the treatment of obesity, in adolescents, and for the reduction of cardiovascular risk. These new indications have widened the patient base and have further established semaglutide as a leader in the GLP-1 therapeutics market.

Supply Constraints May Limit Near-Term Growth:

Notwithstanding the strong fundamentals of demand, current supply shortages in the global market are holding back growth. Capacity constraints and the increasing demand for branded offerings such as Wegovy and Ozempic have led to delays in the initiation of treatment and interruptions in therapy in various geographies. The supply-side issues are currently affecting short-term supply, though the market’s value proposition is highly compelling. In summary, the market for semaglutide is expected to continue its strong double-digit growth rate through 2033, driven by the expanding use of the drug, acceptance by payers, and continued demand for an effective treatment for diabetes and obesity worldwide.

Major Players Analysis Listed in the Semaglutide Market Report are

Semaglutide Market Segmentation Analysis:

By Product

Ozempic held the largest share of around 60.94% in 2025 owing to its established effectiveness in treating type 2 diabetes, its potential for reducing cardiovascular risk, and the convenience of a once-a-week dosing schedule. The wegovy segment is anticipated to achieve the highest CAGR of nearly 10.86% during the 2026–2033 period, driven by its FDA and EMA approval for chronic weight management in adults and adolescents.

Need Any Customization Research on Semaglutide Market, Enquire Now: https://www.snsinsider.com/enquiry/9268

By Route of Administration

The parenteral segment held the largest revenue share of approximately 88.80% in 2025, due to semaglutide being currently only available in injectable over. Oral segment is predicted to grow at the strongest CAGR of approximately 10.88% during 2026–2033, which is being fueled by the growing preference for non-invasive treatment, including Rybelsus.

By Application

Type 2 diabetes mellitus accounted for the largest share of the semaglutide market with about 70.40%, driven by the drug’s demonstrated reduction in HbA1c, weight loss, and cardiovascular risk. The obesity is slated to grow at the fastest rate with a CAGR of around 10.83% throughout the forecast period of 2026–2033, owing to the rising global obesity prevalence and the drug’s effectiveness for substantial weight reduction.

Distribution Channel

The retail pharmacies held the largest revenue share of around 56.61% in the semaglutide market in 2024, owing to easy availability, robust distribution, and increasing consumer inclination for easy prescription refill orders. The online pharmacies segment is projected to register the highest CAGR of around 11.49% during the forecast period of 2025-2032, fueled by the growing digital acceptance, ease, private buying, and broader telemedicine.

Semaglutide Market Regional Insights:

Due to the high prevalence of type 2 diabetes and obesity, particularly in the U.S., North America held the largest revenue share of the semaglutide market in 2025, at around 70.60%. Other factors that support market leadership include strong healthcare systems, early adoption of cutting-edge GLP-1 treatments like Ozempic and Wegovy, and advantageous reimbursement.

Asia Pacific emerges as the fastest-growing region with the highest CAGR of 11.71%, as a result of an explosion of type 2 diabetes and obesity, particularly in countries including China, India, Japan, and South Korea.

Recent Developments:

Purchase Single User PDF of Semaglutide Market Report (20% Discount): https://www.snsinsider.com/checkout/9268

Exclusive Sections of the Report (The USPs):

Access Complete Report Details of Semaglutide Market Analysis & Outlook: https://www.snsinsider.com/reports/semaglutide-market-9268

About Us:

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.